35 U.S.C. § 101: Subject Matter Eligibility Impacts a Wide Range of Technology

Recent developments relating to subject matter eligibility under 35 U.S.C. § 101 may impact several different industries. We will discuss concerns relevant to protecting your company’s products/services and evaluating the portfolios of others. The § 101 concerns reach most of today’s technology, including medical devices, diagnostics, software-related technology such as AI, machine learning, and robotics, and even pharmaceutical treatments. 

We will discuss the following topics:

• The convergence of abstract ideas and natural phenomenon impacting several industries 
• A recent Federal Circuit decision holding a pharmaceutical treatment claim ineligible under § 101, with a comparison to prior law involving treatment claims 
• Practical approaches dealing with § 101 at the USPTO and in court 
• An update on congressional activity addressing § 101
• An in-depth overview of recent Federal Circuit § 101 cases

Recorded: View On-Demand

Speakers:
Paul Barker
Arpita Bhattacharyya, Ph.D.
Aaron Capron